Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · XBiotech Inc. (XBIT)

XBiotech appoints Sushma Shivaswamy and Jan-Paul Simard as co-CEOs

Neutral Impact 4 of 5 leadership Written later

XBiotech's board appointed Dr. Sushma Shivaswamy, who had been interim CEO since December 2025 and remains Chief Scientific Officer, and Jan-Paul Simard as co-chief executive officers effective October 23, 2026. Simard is the son of founder John Simard, and his employment agreement includes a one-time grant of 2,000,000 stock options, which shareholders may weigh alongside the leadership change.

Key points

  • Dr. Sushma Shivaswamy, 48, has been with XBiotech for 17 years and will continue as Chief Scientific Officer with an annual salary of $750,000.
  • Jan-Paul Simard, 24, joined in 2012; his Executive Employment Agreement is dated October 26, 2026, with a base salary of $150,000, prorated through the end of 2026.
  • Simard's initial grant is 2,000,000 stock options, exercisable over ten years and vesting over three years in six-month intervals.

The filing

CompanyXBiotech Inc. (XBIT)
Form8-K, current report
Filed with the SECOct 26, 2026, 9:39 AM ET
Accession number0001171843-26-006810

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 26, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.